Pediatr Infect Dis J. 2025 Aug 12. doi: 10.1097/INF.0000000000004922. Online ahead of print.
ABSTRACT
BACKGROUND: Multisystem inflammatory syndrome in children (MIS-C) is a post-COVID-19 condition resembling Kawasaki disease, including developing coronary aneurysms. Optimal treatment remains uncertain. This study aims to identify effective therapies for preventing aneurysms in MIS-C and associated risk factors.
METHODS: This multicenter, ambispective study included hospitalized patients 0-18 years old with MIS-C between March 2020 and June 2023 from cohorts in Poland, Spain, Catalonia and Colombia. Logistic regression analyzed aneurysm risk factors. Treatment efficacy was assessed using Kaplan-Meier and Cox proportional hazards models, with post hoc Tukey’s tests for pairwise comparisons.
RESULTS: Among 853 patients, 33 (4%) developed aneurysms, with a median age of 5.86 years (interquartile range, 3.00-11.7). All immunomodulatory treatments reduced aneurysm risk compared with no immunomodulatory treatment: corticosteroids + intravenous immunoglobulin (IVIG) [odds ratio (OR): 0.29; 95% confident interval (CI): 0.13-0.68], corticosteroids alone (OR: 0.27; 95% CI: 0.04-1.02) and IVIG alone (OR: 0.49; 95% CI: 0.18-1.28). Kaplan-Meier analysis showed a significantly lower 7-day aneurysm-free probability without immunomodulatory treatment (92%; 95% CI: 87%-96%, P = 0.011). Hazard ratios indicated a reduction in aneurysm risk with corticosteroids+IVIG [hazard ratio (HR) = 0.29; 95% CI: 0.13-0.65], corticosteroids alone (HR = 0.25; 95% CI: 0.06-1.13) and IVIG alone (HR = 0.49; 95% CI: 0.19-1.25), but no significant differences were observed between these treatments. No additional aneurysm risk factors were identified.
CONCLUSIONS: Corticosteroids, IVIG and their combination appear to be protective against aneurysms in children with MIS-C compared with no immunomodulatory treatment. Although the 3 therapies showed no significant differences when compared with each other, only the combination significantly reduced the risk. Corticosteroids may still be a useful option when IVIG is limited.
PMID:40829142 | DOI:10.1097/INF.0000000000004922
